SandboxAQ Highlights AI-Driven Drug Discovery Advances at Barcelona Scientific Events

According to a recent LinkedIn post from SandboxAQ, the company plans to participate in two Barcelona conferences focused on AI-driven drug discovery. The post highlights presentations at the Free Energy Workshop, where SandboxAQ researchers will discuss NEX, a computational method for predicting drug–target binding, and a case study on a Parkinson’s-related target.

The LinkedIn post suggests that NEX delivers predictions aligned with experimental measurements and is designed to handle complex, flexible proteins that have been challenging to model. The Parkinson’s case study reportedly uses AI-guided screening of more than 5 million compounds to identify novel binding sites on a protein with limited structural data.

As shared in the post, SandboxAQ will also join the inaugural CoFold Summit, a scientific forum focused on co-folding, or AI-based prediction of protein–drug structural interactions. The company is further increasing its visibility by hosting the post-Summit reception, indicating an active role in the emerging community around computational drug design.

For investors, the post points to SandboxAQ’s efforts to position its technology at the forefront of AI-enabled drug discovery workflows. If NEX and related approaches gain traction with pharmaceutical and biotech partners, this could support future revenue opportunities in licensing, software-as-a-service, or collaborative R&D agreements.

The emphasis on targets with limited structural data underscores a potential competitive angle, as success in these harder problems could differentiate SandboxAQ’s platform. Participation in specialized forums like the Free Energy Workshop and CoFold Summit may also help the company attract talent, validate its methods with peers, and expand its network of prospective customers in the life sciences sector.